16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Endothelial cells play a key role in the regulation of disease. Defective regulation of endothelial cell homeostasis may cause mesenchymal activation of other endothelial cells or neighboring cell types, and in both cases contributes to organ fibrosis. Regulatory control of endothelial cell homeostasis is not well studied. Diabetes accelerates renal fibrosis in mice lacking the endothelial glucocorticoid receptor (GR), compared to control mice. Hypercholesterolemia further enhances severe renal fibrosis. The fibrogenic phenotype in the kidneys of diabetic mice lacking endothelial GR is associated with aberrant cytokine and chemokine reprogramming, augmented Wnt signaling and suppression of fatty acid oxidation. Both neutralization of IL-6 and Wnt inhibition improve kidney fibrosis by mitigating mesenchymal transition. Conditioned media from endothelial cells from diabetic mice lacking endothelial GR stimulate Wnt signaling-dependent epithelial-to-mesenchymal transition in tubular epithelial cells from diabetic controls. These data demonstrate that endothelial GR is an essential antifibrotic molecule in diabetes.

          Abstract

          The endothelial glucocorticoid receptor plays a key role in the regulation of many diseases, including diabetes. Loss of this receptor results in accelerated renal fibrosis, a heightened inflammatory milieu, augmented Wnt signaling and suppression of fatty acid oxidation in diabetic kidneys.

          Related collections

          Most cited references61

          • Record: found
          • Abstract: found
          • Article: not found

          Origin and function of myofibroblasts in kidney fibrosis.

          Myofibroblasts are associated with organ fibrosis, but their precise origin and functional role remain unknown. We used multiple genetically engineered mice to track, fate map and ablate cells to determine the source and function of myofibroblasts in kidney fibrosis. Through this comprehensive analysis, we identified that the total pool of myofibroblasts is split, with 50% arising from local resident fibroblasts through proliferation. The nonproliferating myofibroblasts derive through differentiation from bone marrow (35%), the endothelial-to-mesenchymal transition program (10%) and the epithelial-to-mesenchymal transition program (5%). Specific deletion of Tgfbr2 in α-smooth muscle actin (αSMA)(+) cells revealed the importance of this pathway in the recruitment of myofibroblasts through differentiation. Using genetic mouse models and a fate-mapping strategy, we determined that vascular pericytes probably do not contribute to the emergence of myofibroblasts or fibrosis. Our data suggest that targeting diverse pathways is required to substantially inhibit the composite accumulation of myofibroblasts in kidney fibrosis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development.

            Renal fibrosis is the histological manifestation of a progressive, usually irreversible process causing chronic and end-stage kidney disease. We performed genome-wide transcriptome studies of a large cohort (n = 95) of normal and fibrotic human kidney tubule samples followed by systems and network analyses and identified inflammation and metabolism as the top dysregulated pathways in the diseased kidneys. In particular, we found that humans and mouse models with tubulointerstitial fibrosis had lower expression of key enzymes and regulators of fatty acid oxidation (FAO) and higher intracellular lipid deposition compared to controls. In vitro experiments indicated that inhibition of FAO in tubule epithelial cells caused ATP depletion, cell death, dedifferentiation and intracellular lipid deposition, phenotypes observed in fibrosis. In contrast, restoring fatty acid metabolism by genetic or pharmacological methods protected mice from tubulointerstitial fibrosis. Our results raise the possibility that correcting the metabolic defect in FAO may be useful for preventing and treating chronic kidney disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition.

              Fibroblasts are key mediators of fibrosis in the kidney and other organs, but their origin during fibrosis is still not completely clear. Activated fibroblasts likely arise from resident quiescent fibroblasts via epithelial-to-mesenchymal transition and from the bone marrow. Here, we demonstrate that endothelial cells also contribute to the emergence of fibroblasts during kidney fibrosis via the process of endothelial-to-mesenchymal transition (EndMT). We examined the contribution of EndMT to renal fibrosis in three mouse models of chronic kidney disease: (1) Unilateral ureteral obstructive nephropathy, (2) streptozotocin-induced diabetic nephropathy, and (3) a model of Alport renal disease. Approximately 30 to 50% of fibroblasts coexpressed the endothelial marker CD31 and markers of fibroblasts and myofibroblasts such as fibroblast specific protein-1 and alpha-smooth muscle actin. Endothelial lineage tracing using Tie2-Cre;R26R-stop-EYFP transgenic mice further confirmed the presence of EndMT-derived fibroblasts. Collectively, our results demonstrate that EndMT contributes to the accumulation of activated fibroblasts and myofibroblasts in kidney fibrosis and suggest that targeting EndMT might have therapeutic potential.
                Bookmark

                Author and article information

                Contributors
                Julie.goodwin@yale.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                22 April 2021
                22 April 2021
                2021
                : 12
                : 2368
                Affiliations
                [1 ]GRID grid.47100.32, ISNI 0000000419368710, Department of Pediatrics, , Yale University School of Medicine New Haven, ; New Haven, CT USA
                [2 ]GRID grid.47100.32, ISNI 0000000419368710, Vascular Biology and Therapeutics Program, , Yale University School of Medicine New Haven, ; New Haven, CT USA
                [3 ]GRID grid.411998.c, ISNI 0000 0001 0265 5359, Department of Diabetology and Endocrinology, , Kanazawa Medical University, ; Uchinada, Japan
                [4 ]GRID grid.47100.32, ISNI 0000000419368710, Department of Surgery, , Yale University School of Medicine New Haven, ; New Haven, CT USA
                [5 ]GRID grid.281208.1, ISNI 0000 0004 0419 3073, Department of Surgery, , VA Connecticut Healthcare System, ; West Haven, CT USA
                [6 ]GRID grid.47100.32, ISNI 0000000419368710, Department of Comparative Medicine, , Yale University School of Medicine New Haven, ; New Haven, CT USA
                [7 ]GRID grid.47100.32, ISNI 0000000419368710, Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM), , Yale University School of Medicine New Haven, ; New Haven, CT USA
                [8 ]GRID grid.47100.32, ISNI 0000000419368710, Department of Pathology, , Yale University School of Medicine New Haven, ; New Haven, CT USA
                Author information
                http://orcid.org/0000-0002-9563-502X
                http://orcid.org/0000-0003-2711-1539
                http://orcid.org/0000-0001-5022-7367
                http://orcid.org/0000-0002-3950-1924
                http://orcid.org/0000-0002-8986-8695
                Article
                22617
                10.1038/s41467-021-22617-y
                8062600
                33888696
                0d62fbc1-77dd-4ee5-bd85-c4a955f60162
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 18 February 2020
                : 23 March 2021
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Uncategorized
                cardiovascular biology,diabetes,molecular medicine,renal fibrosis
                Uncategorized
                cardiovascular biology, diabetes, molecular medicine, renal fibrosis

                Comments

                Comment on this article